Guillain-Barré syndrome: immunopathogenesis and therapeutic targets.

Shan LiuWei Wei ZhangLinpei Jia Hong-Liang Zhang

Published in: Expert opinion on therapeutic targets (2024)

The association with SARS-CoV-2 remains uncertain, with geographical differences that are difficult to explain. Evidence and guidelines are lacking for the decision-making of initiating immunomodulatory therapies in mildly affected patients or patients with regional subtypes of GBS.

Keyphrases

sars cov
end stage renal disease
decision making
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes